Free Trial

Sangamo Therapeutics (SGMO) Competitors

Sangamo Therapeutics logo
$0.59 -0.01 (-2.02%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$0.60 +0.01 (+2.12%)
As of 07/25/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SGMO vs. LXRX, MYGN, EBS, RIGL, XOMA, VSTM, VNDA, CBIO, CDXS, and AGEN

Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Crescent Biopharma (CBIO), Codexis (CDXS), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.

Sangamo Therapeutics vs. Its Competitors

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Lexicon Pharmaceuticals presently has a consensus target price of $3.67, suggesting a potential upside of 233.33%. Sangamo Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 668.44%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexicon Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Sangamo Therapeutics
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Lexicon Pharmaceuticals and 2 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 1.08 beat Lexicon Pharmaceuticals' score of 0.76 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lexicon Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sangamo Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lexicon Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

Sangamo Therapeutics has a net margin of -124.61% compared to Lexicon Pharmaceuticals' net margin of -568.04%. Lexicon Pharmaceuticals' return on equity of -103.16% beat Sangamo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lexicon Pharmaceuticals-568.04% -103.16% -54.95%
Sangamo Therapeutics -124.61%-345.98%-79.86%

Sangamo Therapeutics has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$31.21M12.74-$200.40M-$0.51-2.16
Sangamo Therapeutics$57.80M2.36-$97.94M-$0.39-1.50

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 13.9% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Sangamo Therapeutics beats Lexicon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SGMO vs. The Competition

MetricSangamo TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$136.54M$3.06B$5.74B$9.54B
Dividend YieldN/A2.36%4.71%4.02%
P/E Ratio-1.5021.3228.4120.06
Price / Sales2.36300.85443.6492.77
Price / CashN/A42.6036.1858.54
Price / Book5.328.328.655.87
Net Income-$97.94M-$55.19M$3.25B$258.89M
7 Day Performance14.78%5.86%4.31%3.75%
1 Month Performance8.26%19.30%11.60%12.29%
1 Year Performance-32.29%4.32%35.38%17.86%

Sangamo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SGMO
Sangamo Therapeutics
2.3889 of 5 stars
$0.59
-2.0%
$4.50
+668.4%
-32.3%$136.54M$57.80M-1.50480Positive News
LXRX
Lexicon Pharmaceuticals
2.3874 of 5 stars
$1.23
flat
$3.67
+198.1%
-54.0%$444.63M$31.08M-2.41140
MYGN
Myriad Genetics
4.6691 of 5 stars
$4.45
-0.4%
$14.38
+223.2%
-83.9%$410.20M$837.60M-3.972,700News Coverage
Positive News
EBS
Emergent Biosolutions
4.3333 of 5 stars
$6.93
+0.0%
$14.33
+106.8%
-48.8%$376.27M$1.04B-2.562,420News Coverage
Positive News
RIGL
Rigel Pharmaceuticals
3.3437 of 5 stars
$19.59
+4.2%
$36.40
+85.8%
+87.6%$350.07M$179.28M9.46160Positive News
XOMA
XOMA Royalty
4.0168 of 5 stars
$25.48
-0.7%
$69.50
+172.8%
-11.7%$305.00M$28.49M-22.1610News Coverage
Analyst Upgrade
VSTM
Verastem
3.5258 of 5 stars
$5.10
-1.2%
$13.38
+162.3%
+107.4%$280.24M$10M-1.5950
VNDA
Vanda Pharmaceuticals
4.7363 of 5 stars
$4.66
-2.5%
$16.50
+254.1%
-23.3%$274.61M$198.77M-6.21290Upcoming Earnings
CBIO
Crescent Biopharma
3.2018 of 5 stars
$13.20
-1.0%
$25.67
+94.4%
N/A$258.06M$10K-0.2950High Trading Volume
CDXS
Codexis
3.4621 of 5 stars
$2.84
+0.7%
$11.00
+287.3%
-15.9%$235.29M$59.35M-2.87250News Coverage
Positive News
AGEN
Agenus
4.2209 of 5 stars
$6.09
-1.0%
$16.33
+168.2%
-9.1%$166.97M$99.52M-0.70440

Related Companies and Tools


This page (NASDAQ:SGMO) was last updated on 7/27/2025 by MarketBeat.com Staff
From Our Partners